Which Medications to Avoid in People at Risk of Delirium: a Systematic Review
Andrew Clegg, John B. Young
Age and Ageing 2011; 40
Background: delirium is a common clinical problem and it is associated with adverse health outcomes. Many medications have been associated with the development of delirium, but a strength associations is still uncertain and it is unclear which medications should be avoided in people at risk of delirium.
Methods: we conducted a systematic review to identify prospective studies that investigated the association between medications and risk of delirium. A sensitivity analysis was performed to construct an evidence hierarchy for the risk of delirium with individual agents.
Results: a total of 18,767 studies were identified by the search strategy. Fourteen studies met the inclusion criteria. Delirium risk appears to be increased with opioids (odds ratio [OR] 2.5, 95% CI 1.2–5.2), benzodiazepines (3.0, 1.3–6.8), dihydropyridines (2.4, 1.0–5.8) and possibly antihistamines (1.8, 0.7–4.5). There appears to be no increased risk with neuroleptics (0.9, 0.6–1.3) or digoxin (0.5, 0.3–0.9). There is uncertainty regarding H2 antagonists, tricyclic antidepressants, antiparkinson medications, steroids, non-steroidal anti-inflammatory drugs and antimuscarinics.
Conclusion: avoiding new prescriptions of benzodiazepines or consider reducing/stopping these medications where possible could reduce the risk of delirium. Opioids should be prescribed with caution in people at risk of delirium, but this should be tempered by observations that untreated severe pain can itself trigger delirium. Caution is also required when prescribing dihydropyridines and antihistamine H1 antagonists for people at risk of delirium and considered individual patient assessment is advocated.
A new frontier in critical care: saving the injuried brain.
Gestire il doloreFlowchart dolore
Gestire la sedazioneFlowchart sedaz/agitaz
Gestire il deliriumFlowchart Delirium
Scheda di lavoro CAM-ICU
Questo sito è stato realizzato grazie al contributo di:
Finanziamento per la Ricerca Indipendente
(Decreto DGS 13456 del 22 dicembre 2010)